The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004.

BACKGROUND Invasive group A Streptococcus (GAS) infection causes significant morbidity and mortality in the United States. We report the current epidemiologic characteristics of invasive GAS infections and estimate the potential impact of a multivalent GAS vaccine. METHODS From January 2000 through December 2004, we collected data from Centers for Disease Control and Prevention's Active Bacterial Core surveillance (ABCs), a population-based system operating at 10 US sites (2004 population, 29.7 million). We defined a case of invasive GAS disease as isolation of GAS from a normally sterile site or from a wound specimen obtained from a patient with necrotizing fasciitis or streptococcal toxic shock syndrome in a surveillance area resident. All available isolates were emm typed. We used US census data to calculate rates and to make age- and race-adjusted national projections. RESULTS We identified 5400 cases of invasive GAS infection (3.5 cases per 100,000 persons), with 735 deaths (case-fatality rate, 13.7%). Case-fatality rates for streptococcal toxic shock syndrome and necrotizing fasciitis were 36% and 24%, respectively. Incidences were highest among elderly persons (9.4 cases per 100,000 persons), infants (5.3 cases per 100,000 persons), and black persons (4.7 cases per 100,000 persons) and were stable over time. We estimate that 8950-11,500 cases of invasive GAS infection occur in the United States annually, resulting in 1050-1850 deaths. The emm types in a proposed 26-valent vaccine accounted for 79% of all cases and deaths. Independent factors associated with death include increasing age; having streptococcal toxic shock syndrome, meningitis, necrotizing fasciitis, pneumonia, or bacteremia; and having emm types 1, 3, or 12. CONCLUSIONS GAS remains an important cause of severe disease in the United States. The introduction of a vaccine could significantly reduce morbidity and mortality due to these infections.

[1]  A. Aseffa,et al.  High diversity of group A streptococcal emm types among healthy schoolchildren in Ethiopia. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  D. McMillan.  StreptAvax (ID Biomedical). , 2006, Current opinion in investigational drugs.

[3]  J. Langley,et al.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Bisno,et al.  Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. Schuchat,et al.  Risk Factors for Pediatric Invasive Group A Streptococcal Disease , 2005, Emerging infectious diseases.

[6]  G. Tyrrell,et al.  Invasive Group A Streptococcal Disease in Alberta, Canada (2000 to 2002) , 2005, Journal of Clinical Microbiology.

[7]  H. Lopardo,et al.  Six-Month Multicenter Study on Invasive Infections Due to Streptococcus pyogenes and Streptococcus dysgalactiae subsp. equisimilis in Argentina , 2005, Journal of Clinical Microbiology.

[8]  J. Vuopio‐Varkila,et al.  The epidemiology of severe Streptococcus pyogenes associated disease in Europe. , 2005, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[9]  R. Kumar,et al.  High diversity of group A Streptococcal emm types in an Indian community: the need to tailor multivalent vaccines. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  James D. Campbell,et al.  Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. , 2004, JAMA.

[11]  R. Tanz,et al.  Group A streptococcal pharyngitis serotype surveillance in North America, 2000-2002. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  K. Kotloff,et al.  Progress in Group A Streptococcal Vaccine Development , 2004, The Pediatric infectious disease journal.

[13]  A. Schuchat,et al.  Invasive Group A Streptococcal Disease: Risk Factors for Adults , 2003, Emerging infectious diseases.

[14]  K. O'Brien,et al.  Prevention of invasive group A streptococcal disease among household contacts of case patients and among postpartum and postsurgical patients: recommendations from the Centers for Disease Control and Prevention. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  K. O'Brien,et al.  Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Reddish,et al.  Immunogenicity of a 26-Valent Group A Streptococcal Vaccine , 2002, Infection and Immunity.

[17]  K. O'Brien,et al.  The changing epidemiology of group a Streptococcus infections , 1997 .

[18]  J. Abramson,et al.  Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. , 1991, The Journal of pediatrics.